The company halted the trial of FLX-787, which was intended to treat amyotrophic lateral sclerosis and a neurological disorder called Charcot-Marie-Tooth disease, on June 13. It cited “oral tolerability concerns,” which indicated that more dose-ranging studies are in order before trials can continue.
As a result, Flex will cut its workforce by 60 percent, and its board is considering a potential sale or merger to remain afloat. While the company expects to incur one-time costs of about $1.1 million or less under the workforce restructuring plan, Flex expects to see costs savings in the third quarter of 2018.
The company will continue to operate with a smaller team to discuss the future of FLX-787.
More articles on supply chain:
Pharmacist recommended: 30 top OTC health products of 2018
Novo Nordisk considers 3k layoffs amid turbulence in US insulin market
Bayer hikes price of 2 cancer drugs by $1k per month
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
